secwatch.observer — SEC 8-K summary
======================================

Issuer:     Ocugen, Inc. (OCGN)
CIK:        0001372299
Form:       8-K
Filed at:   2025-06-05T23:59:59+00:00
Accession:  0001104659-25-056875
Event type: other_material
Sentiment:  positive
Materiality: 0.70
Item codes: 5.07, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Ocugen signs binding term sheet to license OCU400 gene therapy in Korea; up to $11M upfront & milestones
--------------------------------------------------------------------------------

- Upfront license fees and near-term development milestones up to $11M.
- Sales milestones of $1M per $15M net sales in Korea (or $150M+ in first 10 years).
- Royalty of 25% on net sales; Ocugen to manufacture and supply OCU400.
- Estimated 15,000 RP patients in Korea; definitive agreement expected within 60 days.
- OCU400 in Phase 3 with target BLA filing mid-2026.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1372299/000110465925056875/0001104659-25-056875-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1372299/000110465925056875/tm2517307d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-25-056875

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer